리젠엑스바이오(RGNX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $8.03 (-2.25%), 시가총액 $0.34B, 52주 최저~최고 $5.65 ~ $15.98.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the com
리젠엑스바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
리젠엑스바이오의 현재 주가는 $8.03 (-2.25%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
리젠엑스바이오의 시가총액은 약 $0.34B입니다.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates ar